Previously, HCCI analyzed Ozempic medication use in the ESI population and found that the percentage of patients using Ozempic that had a diabetes diagnosis, the condition Ozempic is clinically indicated to treat, had decreased from 92% in 2018 to 77% 2021. This indicated a growing trend of off-label use of Ozempic. Our findings aligned with reports at the time of off-label use of Ozempic for weig...